Wim J. E. van Esch

Wim J. E. van Esch

Auto-generated profile, based on publicly available information

Wim J. E. van Esch

CureVac Netherlands B.V., Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in Blood
Verified
Journal Article
Closed access
PDF file
SVSaskia van der Velden
Saskia van der Velden
TOThijs L. J. van Osch
Thijs L. J. van Osch
ASAmina Seghier
Amina Seghier
ABArthur Bentlage
Arthur Bentlage
JMJuk Yee Mok
Juk Yee Mok
RKRick Kapur
Rick Kapur
Transfusion-related acute lung injury (TRALI) is one of the leading causes of transfusion-related fatalities and, to date, is without available therapies. Here, we investigated the role of the complement system in TRALI. Murine anti–major histocompatibility complex class I antibodies were used in TRALI mouse models, in combination with analyses of plasma samples from patients with TRALI. We found that in vitro complement activation was related to in vivo antibody-mediated TRALI induction, which was correlated with increased macrophage trafficking from the lungs to the blood in a fragment crystallizable region (Fc)-dependent manner and that this was dependent on C5. Human immunoglobulin G 1 variants of the murine TRALI-inducing antibody 34-1-2S, either unable to activate complement and/or bind to Fcγ receptors (FcγRs), revealed an essential role for the complement system, but not for FcγRs, in the onset of 34-1-2S–mediated TRALI in mice. In addition, we found high levels of complement activation in the plasma of patients with TRALI (n = 53), which correlated with elevated neutrophil extracellular trap (NET) markers. In vitro we found that NETs could be formed in a murine, 2-hit model, mimicking TRALI with lipopolysaccharide and C5a stimulation. Collectively, this reveals a critical role of Fc-mediated complement activation in TRALI, with a direct relation to macrophage trafficking from the lungs to the blood and an association with NET formation, suggesting that targeting the complement system may be an attractive therapeutic approach for combating TRALI.

30 September 2024 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
TATyler J. Alban
Tyler J. Alban
NRNadeem Riaz
Nadeem Riaz
PPPrerana Parthasarathy
Prerana Parthasarathy
VMVladimir Makarov
Vladimir Makarov
SKSviatoslav Kendall
Sviatoslav Kendall
TCTimothy A. Chan
Timothy A. Chan

4 April 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
MMMichael V. Martin
Michael V. Martin
SASalvador Aguilar-Rosas
Salvador Aguilar-Rosas
KFKatka Franke
Katka Franke
MPMark Pieterse
Mark Pieterse
JLJamie van Langelaar
Jamie van Langelaar
WKWigard P. Kloosterman
Wigard P. Kloosterman
Identification of immunogenic cancer neoantigens as targets for therapy is challenging. Here, we integrate the whole-genome and long-read transcript sequencing of cancers to identify the collection of neo-open reading frame peptides (NOP) expressed in tumors. We termed this collection of NOPs the tumor framome. NOPs represent tumor-specific peptides that are different from wild-type proteins and may be strongly immunogenic. We describe a class of hidden NOPs that derive from structural genomic variants involving an upstream protein coding gene driving expression and translation of noncoding regions of the genome downstream of a rearrangement breakpoint, i.e., where no gene annotation or evidence for transcription exists. The entire collection of NOPs represents a vast number of possible neoantigens particularly in tumors with many structural genomic variants and a low number of missense mutations. We show that NOPs are immunogenic and epitopes derived from NOPs can bind to MHC class I molecules. Finally, we provide evidence for the presence of memory T cells specific for hidden NOPs in peripheral blood from a patient with lung cancer. This work highlights NOPs as a major source of possible neoantigens for personalized cancer immunotherapy and provides a rationale for analyzing the complete cancer genome and transcriptome as a basis for the detection of NOPs.

27 September 2022 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Open access
TOThijs L.J. van Osch
Thijs L.J. van Osch
TPTamas Pongracz
Tamas Pongracz
DGDionne M. Geerdes
Dionne M. Geerdes
JMJuk Yee Mok
Juk Yee Mok
WEWim J.E. van Esch
Wim J.E. van Esch
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
The formation of alloantibodies directed against class I human leukocyte antigens (HLA) continues to be a clinically challenging complication after platelet transfusions, which can lead to platelet refractoriness (PR) and occurs in approximately 5%–15% of patients with chronic platelet support. Interestingly, anti‐HLA IgG levels in alloimmunized patients do not seem to predict PR, suggesting functional or qualitative differences among anti‐HLA IgG. The binding of these alloantibodies to donor platelets can result in rapid clearance after transfusion, presumably via FcγR‐mediated phagocytosis and/or complement activation, which both are affected by the IgG‐Fc glycosylation. To characterize the Fc glycosylation profile of anti‐HLA class I antibodies formed after platelet transfusion and to investigate its effect on clinical outcome. We screened and captured anti‐HLA class I antibodies (anti‐HLA A2, anti‐HLA A24, and anti‐HLA B7) developed after platelet transfusions in hemato‐oncology patients, who were included in the PREPAReS Trial. Using liquid chromatography‐mass spectrometry, we analyzed the glycosylation profiles of total and anti‐HLA IgG1 developed over time. Subsequently, the glycosylation data was linked to the patients' clinical information and posttransfusion increments. The glycosylation profile of anti‐HLA antibodies was highly variable between patients. In general, Fc galactosylation and sialylation levels were elevated compared to total plasma IgG, which correlated negatively with the platelet count increment. Furthermore, high levels of afucosylation were observed for two patients. These differences in composition of anti‐HLA Fc‐glycosylation profiles could potentially explain the variation in clinical severity between patients.


1 December 1998 in Arthritis & Rheumatism
Verified
Journal Article
Closed access
PDF file
CRCarelle C. Reparon‐Schuijt
Carelle C. Reparon‐Schuijt
WEWim J. E. van Esch
Wim J. E. van Esch
CKCees van Kooten
Cees van Kooten
ELEleonora W. N. Levarht
Eleonora W. N. Levarht
FBFerdinand C. Breedveld
Ferdinand C. Breedveld
CVCornelis L. Verweij
Cornelis L. Verweij